Retina Publications

Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry

Ophthalmology and Therapy

April 2022

Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry

Eye

March 2022

Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry

Acta Ophthalmologica

February 2022

The impact of disease activity on 5-year outcomes in patients undergoing treatment for neovascular age-related macular degeneration

Retina

January 2022

Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis

Translational vision science & technology

November 2021

Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence

Eye

October 2021

Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands

Acta Ophthalmologica

September 2021

Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry

Clinical & Experimental Ophthalmology

September 2021

Neovascular age-related macular degeneration at treatment intervals of 14 weeks or greater

Clinical and Experimental Ophthalmology

August 2021

Association between anatomical and clinical outcomes of neovascular age-related macular degeneration treated with anti-VEGF

Retina

July 2021

Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry

Graefe’s Archive for Clinical and Experimental Ophthalmology

June 2021

Five-year incidence and visual acuity outcomes for intravitreal therapy in bilateral neovascular age-related macular degeneration: Fight Retinal Blindness! Project

Retina

January 2021

Email: ssi.ssr@sydney.edu.au
Phone: (+61) 421 787 808

Level 1, South Block
Sydney Eye Hospital
8 Macquarie Street
Sydney NSW 2000

Retina Publications

Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry

Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry

Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry

The impact of disease activity on 5-year outcomes in patients undergoing treatment for neovascular age-related macular degeneration

Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis

Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence

Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands

Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry

Neovascular age-related macular degeneration at treatment intervals of 14 weeks or greater

Association between anatomical and clinical outcomes of neovascular age-related macular degeneration treated with anti-VEGF

Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry

Five-year incidence and visual acuity outcomes for intravitreal therapy in bilateral neovascular age-related macular degeneration: Fight Retinal Blindness! Project

Follow us

Quick links